2025. Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials. SKIN The Journal of Cutaneous Medicine. 9, 1 (Jan. 2025), s522. DOI:https://doi.org/10.25251/skin.9.supp.522.